This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of prostate전립선의 악성신생물 (전립선암)

A. Classification codes C61 — Malignant neoplasm of prostate (mostly prostatic adenocarcinoma; includes transitional cell carcinoma, squamous cell carcinoma, sarcoma, etc.)
B. Synonyms Prostate cancer, Prostatic adenocarcinoma, prostate-specific antigen (PSA)–related cancer, castration-resistant prostate cancer (mCRPC), hormone-sensitive prostate cancer (mHSPC)
C. Adult onset Very high — occurs mainly at age 50 and over. In Korea it has increased by more than 13% per year since 2017, the fastest rate of increase among cancers in men. Onset before age 50 is rare and is associated with hereditary predisposition such as BRCA2 mutations.
Special Copayment Reduction: V193 | 5 years from the date of cancer patient registration | copayment 5%

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

The modern understanding of prostate cancer was shaped by two landmark discoveries. The first was the demonstration in 1941 by Charles Huggins and Clarence Hodges that blocking male hormones (androgens) has a marked therapeutic effect on prostate cancer; for this discovery Huggins received the 1966 Nobel Prize in Physiology or Medicine. This led to surgical castration (orchiectomy) and later medical castration (LHRH agonists/antagonists) being established as standard treatments for prostate cancer.

The second was the discovery and clinical application of prostate-specific antigen (PSA). PSA was first isolated and identified by Wang et al. in 1979, the US FDA approved it as a prostate cancer monitoring marker in 1986, and in the 1990s PSA-based screening spread, mainly in the United States and Western countries. After PSA screening was introduced, prostate cancer diagnoses surged, but problems of overdiagnosis and overtreatment were also raised, and risk-stratified approaches and the concept of active surveillance subsequently developed.

In Korea, prostate cancer has become the fastest-growing malignancy in men over the past 20 years owing to Westernized dietary habits, population aging and improved access to PSA testing. Since 2017, the annual increase in incidence has exceeded 13%, ranking first in rate of increase among all cancers in men. In treatment, second-generation androgen receptor signaling inhibitors (ARSIs) such as abiraterone and enzalutamide since 2011, PARP inhibitors, and in 2022 177Lu-PSMA-617 radioligand therapy (lutetium-PSMA) have been introduced one after another, rapidly changing the treatment landscape.

2. Causes

The main risk factors for prostate cancer are age, race, family history, genetic predisposition, and diet and lifestyle. Age is the strongest risk factor; the disease is rare at age 50 and under but increases sharply from the 70s. By race, incidence and mortality are highest in African Americans and lowest in Asians, but a pattern of increasing incidence is observed among Asian immigrants assimilated into Western environments.

Family history is an important risk factor; having a first-degree relative with prostate cancer increases the risk 2–3-fold. BRCA2 mutations increase prostate cancer risk 5–8-fold and tend to present in an aggressive form. The degree and duration of androgen (male hormone) exposure are also important, and hyperandrogenic states promote prostate epithelial proliferation. A high-fat diet (especially animal fat), obesity, excessive dairy intake and low vitamin D levels are discussed as risk factors. On the other hand, epidemiologic data suggest that legumes (isoflavones), tomatoes (lycopene) and fish (omega-3) may have protective effects.

Smoking is reported to increase the risk of high-grade prostate cancer and prostate cancer mortality. An association with sexually transmitted infections (such as Trichomonas vaginalis) has also been suggested in some studies but has not been established. Overall, prostate cancer is a multifactorial disease whose development is determined by complex interactions of multiple genetic, environmental and hormonal factors rather than a single cause.

3. Genetics

Prostate cancer differs in treatment response and prognosis by molecular subtype. SPOP mutations (11–15%): SPOP acts as a substrate adaptor of an E3 ubiquitin ligase, and mutation leads to increased Wnt/β-catenin signaling and altered AR (androgen receptor) activity. SPOP-mutant tumors are mutually exclusive with ETS fusions (ERG, etc.) and respond relatively well to ARSIs. ETS fusions (TMPRSS2-ERG, 50%) result in overexpression of the ERG transcription factor driven by the androgen-responsive TMPRSS2 promoter, and are the most common somatic rearrangement in prostate cancer.

Biallelic CDK12 loss is observed in about 7% of mCRPC and is characterized by focal tandem duplications and increased gene fusions. This subtype is mutually exclusive with DNA homologous recombination defects and MSI-H, and some responses to immune checkpoint inhibitors have been observed. Mutations in HR repair genes such as BRCA1/2, ATM, CDK12, PALB2 (about 25% of all mCRPC) confer sensitivity to PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib), and on this basis companion diagnostics have become an essential element of treatment selection. PTEN loss and PIK3CA mutations are associated with PI3K/AKT pathway activation, and this pathway interacts with AR, contributing to ARSI resistance. TP53 and RB1 loss are associated with neuroendocrine differentiation and form the molecular background of ARSI resistance.

Pharmacogenomically, AR amplification and AR splice variant-7 (AR-V7) expression are major mechanisms of resistance to enzalutamide and abiraterone, and testing for AR-V7 in circulating tumor cells is used clinically to choose between ARSI and chemotherapy. Expression of PSMA (prostate-specific membrane antigen) is the therapeutic target of 177Lu-PSMA-617 radioligand therapy and the basis of PSMA PET-CT imaging.

4. General epidemiology

Worldwide, prostate cancer is the second most common malignancy in men (after lung cancer) and the fifth leading cause of cancer-related death. In 2020, about 1.41 million new cases were diagnosed worldwide. Incidence varies up to 25-fold by race and region, being highest among African Americans and people of West Indian descent and lowest among Asians living in Asia.

In Korea, prostate cancer ranks first in the rate of increase of cancer incidence in men. Since 2017 it has shown an annual increase of more than 13%, mainly due to wider PSA testing and population aging. The PSA testing rate among men aged 40 and over was only 7.3% as of 2016, lower than in Western countries, but the proportion of early diagnoses is increasing along with the expansion of screening. In Korea it is diagnosed mainly in men in their 60s–70s, and the spread of Western dietary habits is considered not unrelated to the rising incidence. Prostate cancer–specific mortality in Korea is lower than in Western countries, but the absolute number of deaths is increasing.

5. Pathophysiology

The key mechanism of prostate cancer development is activation of the androgen receptor (AR) signaling pathway. Normal prostate epithelial cells depend on androgen signaling (mainly dihydrotestosterone, DHT) via AR for survival and proliferation. When early somatic abnormalities such as the TMPRSS2-ERG fusion occur, AR-responsive genes are abnormally activated, forming prostatic intraepithelial neoplasia (PIN), which then progresses to invasive adenocarcinoma.

Reactivation of AR after androgen deprivation therapy (ADT) is the key to the transition to castration resistance. AR gene amplification, mutations in the AR ligand-binding domain (converting antagonists into agonists), formation of AR splice variants (such as AR-V7, active without the ligand-binding domain), intracellular androgen synthesis (intracrine pathway) and coactivator overexpression are the molecular mechanisms of castration resistance. In response, abiraterone (CYP17A1 inhibition, blocking androgen synthesis) and enzalutamide/apalutamide/darolutamide (competitive inhibition of AR ligand binding, blocking nuclear translocation) were developed. Neuroendocrine differentiation is a major mechanism of ARSI resistance that occurs with loss of AR, with combined loss of TP53 and RB1 as the key molecular event.

6. Symptoms

Early prostate cancer is mostly asymptomatic and is found incidentally by PSA screening. When symptoms are present, lower urinary tract symptoms (LUTS) similar to benign prostatic hyperplasia (BPH) predominate: frequency, nocturia, urgency, weak stream, hesitancy and a sensation of incomplete emptying. These symptoms appear when the tumor compresses the urethra or invades the bladder neck.

In advanced prostate cancer, bone pain due to bone metastasis (mainly lumbar spine, pelvis, thoracic spine) is common, and with spinal metastasis, lower limb paralysis and bladder and rectal dysfunction due to nerve compression (oncologic cord compression) can occur as an emergency. Hematuria, hemospermia, erectile dysfunction, anemia, weight loss and general fatigue may appear as symptoms of advanced disease. With extensive lymph node metastasis, lower limb edema (lymphedema) may develop.

7. Signs

Prostate cancer is suspected when a nodule, induration, irregular surface or asymmetry of the prostate is palpated on digital rectal examination (DRE). A normal prostate is chestnut-shaped, smooth and symmetric with a palpable median sulcus, whereas a cancerous lesion feels like a hard, irregular nodule. DRE alone has low sensitivity and must be combined with PSA.

Elevated serum PSA is the key biochemical sign; 4 ng/mL or higher is considered abnormal, but applying age-specific reference ranges is more accurate. PSA-derived indices such as PSA velocity, PSA density, the free PSA ratio (free/total PSA) and the Prostate Health Index (PHI) increase the accuracy of prostate cancer prediction. With bone metastasis, a bone scan shows multiple areas of increased radionuclide uptake. PSMA PET-CT shows excellent sensitivity for evaluating biochemical recurrence and metastatic lesions.

8. Screening

Prostate cancer screening centers on PSA measurement but remains controversial. Large randomized controlled trials (ERSPC, PLCO) reported that PSA screening can reduce prostate cancer mortality by 25–30%, but the harms of overdiagnosis (detection of clinically insignificant cancer) and overtreatment (unnecessary prostate biopsy, surgery, radiotherapy, etc.) were also confirmed.

Most current guidelines recommend shared decision-making about PSA screening for men aged 50 and over, or from age 40–45 for high-risk groups (men of African descent, BRCA2 mutation carriers, those with a family history). In Korea, PSA testing is not included in the national cancer screening program, and the Korean Urological Association recommends that men aged 50 and over be given sufficient information about PSA screening and then decide for themselves. Screening strategies are evolving so that prior multiparametric MRI (mpMRI) reduces unnecessary biopsies and increases the detection rate of clinically significant cancer.

9. Diagnosis

The diagnosis is confirmed by the pathologic findings of prostate biopsy. Transrectal ultrasound–guided biopsy (TRUS-guided biopsy) or transperineal biopsy is used, and recently mpMRI-targeted biopsy (fusion biopsy) has emerged as the standard. MRI-TRUS fusion or software-based targeted biopsy increases the detection rate of clinically significant cancer (Gleason ≥7) and reduces overdiagnosis of clinically insignificant cancer.

Pathology reports use the ISUP (International Society of Urological Pathology) Grade Groups (Grade Group 1–5) (Gleason score 6→GG1, 3+4=7→GG2, 4+3=7→GG3, 8→GG4, 9–10→GG5). For staging, abdominal and pelvic CT, MRI and bone scan are performed, and PSMA PET-CT detects lymph node, bone and visceral metastases with far greater sensitivity than conventional imaging. In high-risk or metastatic disease, comprehensive genomic profiling (CGP) is used to identify HR repair mutations such as BRCA1/2 and ATM and MSI status, to assess eligibility for PARP inhibitors and immune checkpoint inhibitors. Liquid biopsies such as ctDNA and AR-V7 are also used to monitor treatment resistance.

10. Treatment

Treatment is determined by stage and risk stratification. For localized low-risk (GG1) prostate cancer, active surveillance is the primary recommended option, and more than 50% need no treatment over 5 years of follow-up. For surgery (radical prostatectomy), robot-assisted laparoscopic surgery (RARP) is the global standard, and nerve sparing allows preservation of continence and erectile function. External beam radiotherapy (EBRT) or brachytherapy is as effective as surgery and is used mainly in older patients or those unfit for surgery.

In metastatic hormone-sensitive prostate cancer (mHSPC), ADT + ARSI (enzalutamide, abiraterone, apalutamide, darolutamide) combination therapy is the standard, and in high-risk disease triplet therapy adding docetaxel (ADT + ARSI + docetaxel) provides the greatest survival benefit. In metastatic castration-resistant prostate cancer (mCRPC), sequential ARSI therapy, docetaxel/cabazitaxel chemotherapy, PARP inhibitors (BRCA1/2 mutations), 177Lu-PSMA-617 (lutetium-PSMA) radioligand therapy (high PSMA expression) and pembrolizumab (MSI-H) are used. For bone metastases, zoledronic acid, denosumab and radium-223 (Ra-223) therapy are applied. The joint clinical practice guideline of the Korean Urological Association and the Korean Society of Medical Oncology was updated in 2023 and is applied in clinical practice.

11. Prognosis

The prognosis of prostate cancer varies widely with stage at diagnosis and treatment. The 5-year survival rate for localized prostate cancer is nearly 100%, and prostate cancer–specific mortality is very low when it is detected early.

Stage/risk5-year prostate cancer–specific survival
Localized (stage I–II)>99%
Locally advanced (stage III)95%
Distant metastasis (stage IV, historical)30–35%
mCRPC (including modern treatment)Median OS 18–24 months → recently improved

With the recent introduction of intensified combination therapy in mHSPC and 177Lu-PSMA-617 in mCRPC, survival in metastatic prostate cancer is being greatly prolonged. In mCRPC patients with BRCA2 mutations, olaparib significantly improved radiographic progression-free survival (PROfound study). Overall, with appropriate treatment, prostate cancer is a cancer in which high long-term survival can be expected even in older men.

12. Prevention

There is still no established evidence-based pharmacologic prevention for prostate cancer, but lifestyle improvement is important. Avoiding a Westernized diet: reduce red meat, processed meat and high-fat foods; a diet centered on vegetables, fruit, legumes and whole grains is recommended. Maintaining a normal body weight (obesity is associated with an increased risk of high-grade prostate cancer). Smoking cessation (associated with prostate cancer aggressiveness and mortality). Epidemiologic data indicate that regular physical activity helps lower prostate cancer risk and improve prognosis.

Clinical trials have confirmed that 5α-reductase inhibitors (finasteride, dutasteride) can reduce the occurrence of low-grade prostate cancer by 25%, but because of the possibility of increased high-grade cancer and sexual side effects, routine prescription for prevention is not recommended. Vitamin E and selenium supplementation are not recommended because they have no preventive effect against prostate cancer or may even increase the risk. For genetically high-risk groups such as BRCA mutation carriers, starting PSA screening early to maximize the chance of early diagnosis is currently the best strategy.


13. References

  1. Huggins C, Hodges CV. Studies on prostatic cancer. I: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293–297.
  2. de Bono J, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–2102.
  3. Sartor O, et al. Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–1103.
  4. Kim KH, et al. Short- and long-term anticipation of prostate cancer incidence in Korea. Cancer Res Treat. 2024. PMC10854490.
  5. EAU-EANM-ESTRO-ESUR-ISUP-SIOG. Guidelines on Prostate Cancer. 2025.
  6. Abida W, et al. Genomic correlates of clinical outcome in advanced prostate cancer. PNAS. 2019;116(23):11428–11436.
  7. Fizazi K, et al. Enzalutamide plus leuprolide in patients with nonmetastatic castration-resistant prostate cancer. N Engl J Med. 2019;381:125–135.
  8. Korean Urological Association. Clinical practice recommendations for prostate cancer. 2023.
  9. Beltran H, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019;25(23):6916–6924.
  10. Sweeney CJ, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–746.